The molecular conversations of sarcomas: exosomal non-coding RNAs in tumor's biology and their translational prospects.
Exosomes
LncRNAs
Non-coding RNAs
Sarcomas
Tumor microenvironment
circRNA
microRNAs
Journal
Molecular cancer
ISSN: 1476-4598
Titre abrégé: Mol Cancer
Pays: England
ID NLM: 101147698
Informations de publication
Date de publication:
22 Aug 2024
22 Aug 2024
Historique:
received:
04
07
2024
accepted:
13
08
2024
medline:
23
8
2024
pubmed:
23
8
2024
entrez:
22
8
2024
Statut:
epublish
Résumé
Exosomes mediate cell-to-cell crosstalk involving a variety of biomolecules through an intricate signaling network. In recent years, the pivotal role of exosomes and their non-coding RNAs cargo in the development and progression of several cancer types clearly emerged. In particular, tumor bulk and its microenvironment co-evolve through cellular communications where these nanosized extracellular vesicles are among the most relevant actors. Knowledge about the cellular, and molecular mechanisms involved in these communications will pave the way for novel exosome-based delivery of therapeutic RNAs as well as innovative prognostic/diagnostic tools. Despite the valuable therapeutic potential and clinical relevance of exosomes, their role on sarcoma has been vaguely reported because the rarity and high heterogeneity of this type of cancer. Here, we dissected the scientific literature to unravel the multifaceted role of exosomal non-coding RNAs as mediator of cell-to-cell communications in the sarcoma subtypes.
Identifiants
pubmed: 39174949
doi: 10.1186/s12943-024-02083-y
pii: 10.1186/s12943-024-02083-y
doi:
Substances chimiques
RNA, Untranslated
0
Biomarkers, Tumor
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
172Subventions
Organisme : Ministero della Salute
ID : Ricerca Corrente 2024
Organisme : Ministero della Salute
ID : Ricerca Corrente 2024
Organisme : Ministero della Salute
ID : Ricerca Corrente 2024
Organisme : Ministero della Salute
ID : Ricerca Corrente 2024
Organisme : Ministero della Salute
ID : Ricerca Corrente 2024
Organisme : Ministero della Salute
ID : Ricerca Corrente 2024
Informations de copyright
© 2024. The Author(s).
Références
Cosci I, Del Fiore P, Mocellin S, Ferlin A. Gender differences in soft tissue and bone sarcoma: a narrative review. Cancers. 2023;16:201.
pubmed: 38201628
pmcid: 10778120
doi: 10.3390/cancers16010201
Chmiel P, Krotewicz M, Szumera-Ciećkiewicz A, Bartnik E, Czarnecka AM, Rutkowski P. Review on Lymph Node Metastases, Sentinel Lymph Node Biopsy, and Lymphadenectomy in Sarcoma. Curr Oncol Tor Ont. 2024;31:307–23.
doi: 10.3390/curroncol31010020
Skubitz KM, D’Adamo DR. Sarcoma. Mayo Clin Proc. 2007;82:1409–32.
pubmed: 17976362
doi: 10.4065/82.11.1409
Laurino S, Omer LC, Albano F, Marino G, Bianculli A, Solazzo AP, et al. Radiation-induced sarcomas: a single referral cancer center experience and literature review. Front Oncol. 2022;12:986123.
pubmed: 36249019
pmcid: 9561616
doi: 10.3389/fonc.2022.986123
Wallander K, Öfverholm I, Boye K, Tsagkozis P, Papakonstantinou A, Lin Y, et al. Sarcoma care in the era of precision medicine. J Intern Med. 2023;294:690–707.
pubmed: 37643281
doi: 10.1111/joim.13717
Russi S, Sgambato A, Bochicchio AM, Zoppoli P, Aieta M, Capobianco AML, et al. CHIR99021, trough GSK-3β targeting, reduces Epithelioid Sarcoma Cell Proliferation by activating mitotic catastrophe and Autophagy. Int J Mol Sci. 2021;22:11147.
pubmed: 34681807
pmcid: 8538073
doi: 10.3390/ijms222011147
Nakano K, Takahashi S. Precision Medicine in Soft tissue Sarcoma Treatment. Cancers. 2020;12:221.
pubmed: 31963219
pmcid: 7017346
doi: 10.3390/cancers12010221
Grünewald TG, Alonso M, Avnet S, Banito A, Burdach S, Cidre-Aranaz F, et al. Sarcoma treatment in the era of molecular medicine. EMBO Mol Med. 2020;12:e11131.
pubmed: 33047515
pmcid: 7645378
doi: 10.15252/emmm.201911131
Catalano M, O’Driscoll L. Inhibiting extracellular vesicles formation and release: a review of EV inhibitors. J Extracell Vesicles. 9:1703244.
Yokoi A, Ochiya T. Exosomes and extracellular vesicles: rethinking the essential values in cancer biology. Semin Cancer Biol. 2021;74:79–91.
pubmed: 33798721
doi: 10.1016/j.semcancer.2021.03.032
Zhang L, Yu D. Exosomes in cancer development, metastasis, and immunity. Biochim Biophys Acta Rev Cancer. 2019;1871:455–68.
pubmed: 31047959
pmcid: 6542596
doi: 10.1016/j.bbcan.2019.04.004
Dai J, Su Y, Zhong S, Cong L, Liu B, Yang J, et al. Exosomes: key players in cancer and potential therapeutic strategy. Signal Transduct Target Ther. 2020;5:145.
pubmed: 32759948
pmcid: 7406508
doi: 10.1038/s41392-020-00261-0
Raposo G, Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol. 2013;200:373–83.
pubmed: 23420871
pmcid: 3575529
doi: 10.1083/jcb.201211138
Crescitelli R, Lässer C, Jang SC, Cvjetkovic A, Malmhäll C, Karimi N, et al. Subpopulations of extracellular vesicles from human metastatic melanoma tissue identified by quantitative proteomics after optimized isolation. J Extracell Vesicles. 2020;9:1722433.
pubmed: 32128073
pmcid: 7034452
doi: 10.1080/20013078.2020.1722433
Witwer KW, Théry C. Extracellular vesicles or exosomes? On primacy, precision, and popularity influencing a choice of nomenclature. J Extracell Vesicles. 2019;8:1648167.
pubmed: 31489144
pmcid: 6711079
doi: 10.1080/20013078.2019.1648167
Herrmann IK, Wood MJA, Fuhrmann G. Extracellular vesicles as a next-generation drug delivery platform. Nat Nanotechnol. 2021;16:748–59.
pubmed: 34211166
doi: 10.1038/s41565-021-00931-2
Mashouri L, Yousefi H, Aref AR, Ahadi AM, Molaei F, Alahari SK. Exosomes: composition, biogenesis, and mechanisms in cancer metastasis and drug resistance. Mol Cancer. 2019;18:75.
pubmed: 30940145
pmcid: 6444571
doi: 10.1186/s12943-019-0991-5
Welsh JA, Goberdhan DCI, O’Driscoll L, Buzas EI, Blenkiron C, Bussolati B, et al. Minimal information for studies of extracellular vesicles (MISEV2023): from basic to advanced approaches. J Extracell Vesicles. 2024;13:e12404.
pubmed: 38326288
pmcid: 10850029
doi: 10.1002/jev2.12404
Han Q-F, Li W-J, Hu K-S, Gao J, Zhai W-L, Yang J-H, et al. Exosome biogenesis: machinery, regulation, and therapeutic implications in cancer. Mol Cancer. 2022;21:207.
pubmed: 36320056
pmcid: 9623991
doi: 10.1186/s12943-022-01671-0
Hosseinikhah SM, Gheybi F, Moosavian SA, Shahbazi M-A, Jaafari MR, Sillanpää M, et al. Role of exosomes in tumour growth, chemoresistance and immunity: state-of-the-art. J Drug Target. 2023;31:32–50.
pubmed: 35971773
doi: 10.1080/1061186X.2022.2114000
Ye H, Hu X, Wen Y, Tu C, Hornicek F, Duan Z, et al. Exosomes in the tumor microenvironment of sarcoma: from biological functions to clinical applications. J Nanobiotechnol. 2022;20:403.
doi: 10.1186/s12951-022-01609-0
Baietti MF, Zhang Z, Mortier E, Melchior A, Degeest G, Geeraerts A, et al. Syndecan-syntenin-ALIX regulates the biogenesis of exosomes. Nat Cell Biol. 2012;14:677–85.
pubmed: 22660413
doi: 10.1038/ncb2502
Larios J, Mercier V, Roux A, Gruenberg J. ALIX- and ESCRT-III–dependent sorting of tetraspanins to exosomes. J Cell Biol. 2020;219:e201904113.
pubmed: 32049272
pmcid: 7054990
doi: 10.1083/jcb.201904113
Dores MR, Grimsey NJ, Mendez F, Trejo J. ALIX regulates the ubiquitin-independent lysosomal sorting of the P2Y1 purinergic receptor via a YPX3L motif. PLoS ONE. 2016;11:e0157587.
pubmed: 27301021
pmcid: 4907476
doi: 10.1371/journal.pone.0157587
Wenzel EM, Schultz SW, Schink KO, Pedersen NM, Nähse V, Carlson A, et al. Concerted ESCRT and clathrin recruitment waves define the timing and morphology of intraluminal vesicle formation. Nat Commun. 2018;9:2932.
pubmed: 30050131
pmcid: 6062606
doi: 10.1038/s41467-018-05345-8
Trajkovic K, Hsu C, Chiantia S, Rajendran L, Wenzel D, Wieland F, et al. Ceramide triggers budding of exosome vesicles into multivesicular endosomes. Science. 2008;319:1244–7.
pubmed: 18309083
doi: 10.1126/science.1153124
Ma S, Mangala LS, Hu W, Bayaktar E, Yokoi A, Hu W, et al. CD63-mediated cloaking of VEGF in small extracellular vesicles contributes to anti-VEGF therapy resistance. Cell Rep. 2021;36:109549.
pubmed: 34407412
pmcid: 8422976
doi: 10.1016/j.celrep.2021.109549
Yanatori I, Richardson DR, Dhekne HS, Toyokuni S, Kishi F. CD63 is regulated by iron via the IRE-IRP system and is important for ferritin secretion by extracellular vesicles. Blood. 2021;138:1490–503.
pubmed: 34265052
pmcid: 8667049
doi: 10.1182/blood.2021010995
Kowal J, Tkach M, Théry C. Biogenesis and secretion of exosomes. Curr Opin Cell Biol. 2014;29:116–25.
pubmed: 24959705
doi: 10.1016/j.ceb.2014.05.004
Jiang C, Zhang J, Wang W, Shan Z, Sun F, Tan Y, et al. Extracellular vesicles in gastric cancer: role of exosomal lncRNA and microRNA as diagnostic and therapeutic targets. Front Physiol. 2023;14:1158839.
pubmed: 37664422
pmcid: 10469264
doi: 10.3389/fphys.2023.1158839
Shao Y, Dong Y, Zhou J, Lu Z, Chen C, Yuan X, et al. Advances in the study of antisense long–stranded non–coding RNAs in tumors (review). Int J Oncol. 2024;64:22.
pubmed: 38214378
doi: 10.3892/ijo.2024.5610
Yu P, Ye J, Zhao S, Cai Y. lncRNAs are potential prognostic markers in patients with nasopharyngeal carcinoma in China: a systematic review and meta–analysis. Mol Clin Oncol. 2024;20:11.
pubmed: 38213659
doi: 10.3892/mco.2023.2709
Mallela VR, Rajtmajerová M, Trailin A, Liška V, Hemminki K, Ambrozkiewicz F. miRNA and lncRNA as potential tissue biomarkers in hepatocellular carcinoma. Non-Coding RNA Res. 2024;9:24–32.
doi: 10.1016/j.ncrna.2023.10.010
Zhao L, Wu Q, Long Y, Qu Q, Qi F, Liu L, et al. microRNAs: critical targets for treating rheumatoid arthritis angiogenesis. J Drug Target. 2024;32:1–20.
pubmed: 37982157
doi: 10.1080/1061186X.2023.2284097
Nikolova E, Laleva L, Milev M, Spiriev T, Stoyanov S, Ferdinandov D, et al. miRNAs and related genetic biomarkers according to the WHO glioma classification: from diagnosis to future therapeutic targets. Non-Coding RNA Res. 2024;9:141–52.
doi: 10.1016/j.ncrna.2023.10.003
Lu TX, Rothenberg ME. MicroRNA. J Allergy Clin Immunol. 2018;141:1202–7.
pubmed: 29074454
doi: 10.1016/j.jaci.2017.08.034
Svoronos AA, Engelman DM, Slack FJ. OncomiR or tumor suppressor? The duplicity of MicroRNAs in Cancer. Cancer Res. 2016;76:3666–70.
pubmed: 27325641
pmcid: 4930690
doi: 10.1158/0008-5472.CAN-16-0359
Otmani K, Lewalle P. Tumor suppressor miRNA in Cancer cells and the Tumor Microenvironment: mechanism of Deregulation and Clinical implications. Front Oncol. 2021;11:708765.
pubmed: 34722255
pmcid: 8554338
doi: 10.3389/fonc.2021.708765
Tang C, He X, Jia L, Zhang X. Circular RNAs in glioma: molecular functions and pathological implications. Non-Coding RNA Res. 2024;9:105–15.
doi: 10.1016/j.ncrna.2023.10.007
Ashwal-Fluss R, Meyer M, Pamudurti NR, Ivanov A, Bartok O, Hanan M, et al. circRNA biogenesis competes with pre-mRNA splicing. Mol Cell. 2014;56:55–66.
pubmed: 25242144
doi: 10.1016/j.molcel.2014.08.019
Zhang Y, Zhang X-O, Chen T, Xiang J-F, Yin Q-F, Xing Y-H, et al. Circular intronic long noncoding RNAs. Mol Cell. 2013;51:792–806.
pubmed: 24035497
doi: 10.1016/j.molcel.2013.08.017
Jeck WR, Sorrentino JA, Wang K, Slevin MK, Burd CE, Liu J, et al. Circular RNAs are abundant, conserved, and associated with ALU repeats. RNA N Y N. 2013;19:141–57.
doi: 10.1261/rna.035667.112
Abdullah ST, Abdullah SR, Hussen BM, Younis YM, Rasul MF, Taheri M. Role of circular RNAs and gut microbiome in gastrointestinal cancers and therapeutic targets. Non-Coding RNA Res. 2024;9:236–52.
doi: 10.1016/j.ncrna.2023.12.002
Kristensen LS, Andersen MS, Stagsted LVW, Ebbesen KK, Hansen TB, Kjems J. The biogenesis, biology and characterization of circular RNAs. Nat Rev Genet. 2019;20:675–91.
pubmed: 31395983
doi: 10.1038/s41576-019-0158-7
Chen L, Huang C, Wang X, Shan G. Circular RNAs in eukaryotic cells. Curr Genomics. 2015;16:312–8.
pubmed: 27047251
pmcid: 4763969
doi: 10.2174/1389202916666150707161554
Tang X, Ren H, Guo M, Qian J, Yang Y, Gu C. Review on circular RNAs and new insights into their roles in cancer. Comput Struct Biotechnol J. 2021;19:910–28.
pubmed: 33598105
pmcid: 7851342
doi: 10.1016/j.csbj.2021.01.018
Shan C, Zhang Y, Hao X, Gao J, Chen X, Wang K. Biogenesis, functions and clinical significance of circRNAs in gastric cancer. Mol Cancer. 2019;18:136.
pubmed: 31519189
pmcid: 6743094
doi: 10.1186/s12943-019-1069-0
Begliarzade S, Sufianov A, Ilyasova T, Shumadalova A, Sufianov R, Beylerli O, et al. Circular RNA in cervical cancer: fundamental mechanism and clinical potential. Non-Coding RNA Res. 2023;9:116–24.
doi: 10.1016/j.ncrna.2023.11.009
Ma Y, Zheng L, Gao Y, Zhang W, Zhang Q, Xu Y. A comprehensive overview of circRNAs: emerging biomarkers and potential therapeutics in gynecological cancers. Front Cell Dev Biol. 2021;9:709512.
pubmed: 34368160
pmcid: 8335568
doi: 10.3389/fcell.2021.709512
Garlapati P, Ling J, Chiao PJ, Fu J. Circular RNAs regulate cancer-related signaling pathways and serve as potential diagnostic biomarkers for human cancers. Cancer Cell Int. 2021;21:317.
pubmed: 34162394
pmcid: 8220689
doi: 10.1186/s12935-021-02017-4
Zhang X, Wang S, Wang H, Cao J, Huang X, Chen Z, et al. Circular RNA circNRIP1 acts as a microRNA-149-5p sponge to promote gastric cancer progression via the AKT1/mTOR pathway. Mol Cancer. 2019;18:20.
pubmed: 30717751
pmcid: 6360801
doi: 10.1186/s12943-018-0935-5
Yang X, Liu M, Li M, Zhang S, Hiju H, Sun J, et al. Epigenetic modulations of noncoding RNA: a novel dimension of Cancer biology. Mol Cancer. 2020;19:64.
pubmed: 32209098
pmcid: 7092482
doi: 10.1186/s12943-020-01159-9
Pathania AS, Prathipati P, Pandey MK, Byrareddy SN, Coulter DW, Gupta SC, et al. The emerging role of non-coding RNAs in the epigenetic regulation of pediatric cancers. Semin Cancer Biol. 2022;83:227–41.
pubmed: 33910063
doi: 10.1016/j.semcancer.2021.04.015
Yang E, Wang X, Gong Z, Yu M, Wu H, Zhang D. Exosome-mediated metabolic reprogramming: the emerging role in tumor microenvironment remodeling and its influence on cancer progression. Signal Transduct Target Ther. 2020;5:242.
pubmed: 33077737
pmcid: 7572387
doi: 10.1038/s41392-020-00359-5
Bu L, Baba H, Yoshida N, Miyake K, Yasuda T, Uchihara T, et al. Biological heterogeneity and versatility of cancer-associated fibroblasts in the tumor microenvironment. Oncogene. 2019;38:4887–901.
pubmed: 30816343
doi: 10.1038/s41388-019-0765-y
Liu Y, Li C, Lu Y, Liu C, Yang W. Tumor microenvironment-mediated immune tolerance in development and treatment of gastric cancer. Front Immunol. 2022;13:1016817.
pubmed: 36341377
pmcid: 9630479
doi: 10.3389/fimmu.2022.1016817
Xiao Y, Yu D. Tumor microenvironment as a therapeutic target in cancer. Pharmacol Ther. 2021;221:107753.
pubmed: 33259885
doi: 10.1016/j.pharmthera.2020.107753
Luo X, Li Y, Hua Z, Xue X, Wang X, Pang M, et al. Exosomes-mediated tumor metastasis through reshaping tumor microenvironment and distant niche. J Controlled Release. 2023;353:327–36.
doi: 10.1016/j.jconrel.2022.11.050
Wu K, Lin K, Li X, Yuan X, Xu P, Ni P, et al. Redefining Tumor-Associated macrophage subpopulations and functions in the Tumor Microenvironment. Front Immunol. 2020;11:1731.
pubmed: 32849616
pmcid: 7417513
doi: 10.3389/fimmu.2020.01731
Zhang Q, Huang F, Yao Y, Wang J, Wei J, Wu Q, et al. Interaction of transforming growth factor-β-Smads/microRNA-362-3p/CD82 mediated by M2 macrophages promotes the process of epithelial-mesenchymal transition in hepatocellular carcinoma cells. Cancer Sci. 2019;110:2507–19.
pubmed: 31215741
pmcid: 6676115
doi: 10.1111/cas.14101
DeNardo DG, Ruffell B. Macrophages as regulators of tumour immunity and immunotherapy. Nat Rev Immunol. 2019;19:369–82.
pubmed: 30718830
pmcid: 7339861
doi: 10.1038/s41577-019-0127-6
Chen Y, McAndrews KM, Kalluri R. Clinical and therapeutic relevance of cancer-associated fibroblasts. Nat Rev Clin Oncol. 2021;18:792–804.
pubmed: 34489603
pmcid: 8791784
doi: 10.1038/s41571-021-00546-5
Zhang H, Yue X, Chen Z, Liu C, Wu W, Zhang N, et al. Define cancer-associated fibroblasts (CAFs) in the tumor microenvironment: new opportunities in cancer immunotherapy and advances in clinical trials. Mol Cancer. 2023;22:159.
pubmed: 37784082
pmcid: 10544417
doi: 10.1186/s12943-023-01860-5
Monteran L, Erez N. The Dark side of fibroblasts: Cancer-Associated fibroblasts as mediators of Immunosuppression in the Tumor Microenvironment. Front Immunol. 2019;10:1835.
pubmed: 31428105
pmcid: 6688105
doi: 10.3389/fimmu.2019.01835
Li Z, Sun C, Qin Z. Metabolic reprogramming of cancer-associated fibroblasts and its effect on cancer cell reprogramming. Theranostics. 2021;11:8322–36.
pubmed: 34373744
pmcid: 8343997
doi: 10.7150/thno.62378
Li Y, Zhao Z, Liu W, Li X. SNHG3 functions as miRNA sponge to promote breast Cancer cells growth through the metabolic reprogramming. Appl Biochem Biotechnol. 2020;191:1084–99.
pubmed: 31956955
pmcid: 7320061
doi: 10.1007/s12010-020-03244-7
O’Connell JT, Sugimoto H, Cooke VG, MacDonald BA, Mehta AI, LeBleu VS, et al. VEGF-A and Tenascin-C produced by S100A4 + stromal cells are important for metastatic colonization. Proc Natl Acad Sci U S A. 2011;108:16002–7.
pubmed: 21911392
pmcid: 3179047
doi: 10.1073/pnas.1109493108
Kumar V, Patel S, Tcyganov E, Gabrilovich DI. The nature of myeloid-derived suppressor cells in the Tumor Microenvironment. Trends Immunol. 2016;37:208–20.
pubmed: 26858199
pmcid: 4775398
doi: 10.1016/j.it.2016.01.004
Tian X, Shen H, Li Z, Wang T, Wang S. Tumor-derived exosomes, myeloid-derived suppressor cells, and tumor microenvironment. J Hematol OncolJ Hematol Oncol. 2019;12:84.
doi: 10.1186/s13045-019-0772-z
Zhao A, Zhao Z, Liu W, Cui X, Wang N, Wang Y, et al. Carcinoma-associated fibroblasts promote the proliferation and metastasis of osteosarcoma by transferring exosomal LncRNA SNHG17. Am J Transl Res. 2021;13:10094–111.
pubmed: 34650683
pmcid: 8507050
Pan Y, Lin Y, Mi C. Cisplatin-resistant osteosarcoma cell-derived exosomes confer cisplatin resistance to recipient cells in an exosomal circ_103801-dependent manner. Cell Biol Int. 2021;45:858–68.
pubmed: 33325136
doi: 10.1002/cbin.11532
Cuscino N, Raimondi L, De Luca A, Carcione C, Russelli G, Conti L, et al. Gathering Novel circulating Exosomal microRNA in Osteosarcoma Cell lines and possible implications for the Disease. Cancers. 2019;11:1924.
pubmed: 31816885
pmcid: 6966608
doi: 10.3390/cancers11121924
Kohama I, Asano N, Matsuzaki J, Yamamoto Y, Yamamoto T, Takahashi R-U, et al. Comprehensive serum and tissue microRNA profiling in dedifferentiated liposarcoma. Oncol Lett. 2021;22:623.
pubmed: 34285721
pmcid: 8258628
doi: 10.3892/ol.2021.12884
Ehnman M, Chaabane W, Haglund F, Tsagkozis P. The Tumor Microenvironment of Pediatric Sarcoma: mesenchymal mechanisms regulating Cell Migration and Metastasis. Curr Oncol Rep. 2019;21:90.
pubmed: 31418125
pmcid: 6695368
doi: 10.1007/s11912-019-0839-6
Yoshida A, Fujiwara T, Uotani K, Morita T, Kiyono M, Yokoo S, et al. Clinical and functional significance of intracellular and extracellular microRNA-25-3p in Osteosarcoma. Acta Med Okayama. 2018;72:165–74.
pubmed: 29674765
Ye Z, Zheng Z, Peng L. MicroRNA profiling of serum exosomes in patients with osteosarcoma by high-throughput sequencing. J Investig Med off Publ Am Fed Clin Res. 2020;68:893–901.
Uotani K, Fujiwara T, Yoshida A, Iwata S, Morita T, Kiyono M, et al. Circulating MicroRNA-92b-3p as a Novel Biomarker for Monitoring of Synovial Sarcoma. Sci Rep. 2017;7:14634.
pubmed: 29116117
pmcid: 5676745
doi: 10.1038/s41598-017-12660-5
Zhang H, Wang J, Ren T, Huang Y, Yu Y, Chen C, et al. LncRNA CASC15 is upregulated in Osteosarcoma plasma exosomes and CASC15 Knockdown inhibits Osteosarcoma Progression by regulating miR-338-3p/RAB14 Axis. OncoTargets Ther. 2020;13:12055–66.
doi: 10.2147/OTT.S282053
Zhang X-B, Zhang R-H, Su X, Qi J, Hu Y-C, Shi J-T, et al. Exosomes in osteosarcoma research and preclinical practice. Am J Transl Res. 2021;13:882–97.
pubmed: 33841628
pmcid: 8014357
Wang S, Ma F, Feng Y, Liu T, He S. Role of exosomal miR–21 in the tumor microenvironment and osteosarcoma tumorigenesis and progression (review). Int J Oncol. 2020;56:1055–63.
pubmed: 32319566
Raimondi L, De Luca A, Gallo A, Costa V, Russelli G, Cuscino N, et al. Osteosarcoma cell-derived exosomes affect tumor microenvironment by specific packaging of microRNAs. Carcinogenesis. 2020;41:666–77.
pubmed: 31294446
doi: 10.1093/carcin/bgz130
Qi J, Zhang R, Wang Y, Exosomal. Mir-21-5p derived from bone marrow mesenchymal stem cells promote osteosarcoma cell proliferation and invasion by targeting PIK3R1. J Cell Mol Med. 2021;25:11016–30.
pubmed: 34741385
pmcid: 8642676
doi: 10.1111/jcmm.17024
Luo A, Liu H, Huang C, Wei S. Exosome-transmitted circular RNA circ-LMO7 facilitates the progression of osteosarcoma by regulating miR-21-5p/ARHGAP24 axis. Cancer Biol Ther. 2024;25:2343450.
pubmed: 38742566
pmcid: 11095575
doi: 10.1080/15384047.2024.2343450
Jiang M, Jike Y, Liu K, Gan F, Zhang K, Xie M, et al. Exosome-mediated mir-144-3p promotes ferroptosis to inhibit osteosarcoma proliferation, migration, and invasion through regulating ZEB1. Mol Cancer. 2023;22:113.
pubmed: 37461104
pmcid: 10351131
doi: 10.1186/s12943-023-01804-z
Yang H, He C, Feng Y, Jin J. Exosome–delivered miR–486–3p inhibits the progression of osteosarcoma via sponging CircKEAP1/MARCH1 axis components. Oncol Lett. 2024;27:24.
pubmed: 38058466
doi: 10.3892/ol.2023.14157
Yang D, Chen Y, He ZNT, Wang Y, Ke C, Luo Y, et al. Indoleamine 2,3-dioxygenase 1 promotes osteosarcoma progression by regulating tumor-derived exosomal miRNA hsa-miR-23a-3p. Front Pharmacol. 2023;14:1194094.
pubmed: 37284323
pmcid: 10239870
doi: 10.3389/fphar.2023.1194094
Wu C, Li Z, Feng G, Wang L, Xie J, Jin Y, et al. Tumor suppressing role of serum-derived exosomal microRNA-15a in osteosarcoma cells through the GATA binding protein 2/murine double minute 2 axis and the p53 signaling pathway. Bioengineered. 2021;12:8378–95.
pubmed: 34592889
pmcid: 8806960
doi: 10.1080/21655979.2021.1987092
Lin L, Wang H, Guo W, He E, Huang K, Zhao Q. Osteosarcoma-derived exosomal mir-501-3p promotes osteoclastogenesis and aggravates bone loss. Cell Signal. 2021;82:109935.
pubmed: 33529755
doi: 10.1016/j.cellsig.2021.109935
Yan C-F, Xia J, Qun W-S, Bing W-Y, Guo W-J, Yong H-G, et al. Tumor-associated macrophages-derived exo-let-7a promotes osteosarcoma metastasis via targeting C15orf41 in osteosarcoma. Environ Toxicol. 2023;38:1318–31.
pubmed: 36919336
doi: 10.1002/tox.23766
Liu W, Long Q, Zhang W, Zeng D, Hu B, Liu S, et al. miRNA-221-3p derived from M2-polarized tumor-associated macrophage exosomes aggravates the growth and metastasis of osteosarcoma through SOCS3/JAK2/STAT3 axis. Aging. 2021;13:19760–75.
pubmed: 34388111
pmcid: 8386545
doi: 10.18632/aging.203388
Wang Z-G, Deng M-S, Su J-Q, Liu D-B, Zhou Y. Exosomal miR-181a-5p derived from SAOS-2 cells promotes macrophages M2 polarization by targeting RORA. Kaohsiung J Med Sci. 2023;39:124–33.
pubmed: 36468636
doi: 10.1002/kjm2.12623
Wang J-W, Wu X-F, Gu X-J, Jiang X-H. Exosomal miR-1228 from Cancer-Associated fibroblasts promotes Cell Migration and Invasion of Osteosarcoma by directly targeting SCAI. Oncol Res. 2019;27:979–86.
pubmed: 30180920
pmcid: 7848259
doi: 10.3727/096504018X15336368805108
Han F, Pu P, Wang C, Ding X, Zhu Z, Xiang W, et al. Osteosarcoma Cell-Derived Exosomal miR-1307 promotes Tumorgenesis via Targeting AGAP1. BioMed Res Int. 2021;2021:7358153.
pubmed: 33834074
pmcid: 8016573
doi: 10.1155/2021/7358153
Gong L, Bao Q, Hu C, Wang J, Zhou Q, Wei L, et al. Exosomal miR-675 from metastatic osteosarcoma promotes cell migration and invasion by targeting CALN1. Biochem Biophys Res Commun. 2018;500:170–6.
pubmed: 29626470
doi: 10.1016/j.bbrc.2018.04.016
Wolf-Dennen K, Gordon N, Kleinerman ES. Exosomal communication by metastatic osteosarcoma cells modulates alveolar macrophages to an M2 tumor-promoting phenotype and inhibits tumoricidal functions. Oncoimmunology. 2020;9:1747677.
pubmed: 32313728
pmcid: 7153823
doi: 10.1080/2162402X.2020.1747677
Meng C, Yang Y, Feng W, Ma P, Bai R. Exosomal mir-331-3p derived from chemoresistant osteosarcoma cells induces chemoresistance through autophagy. J Orthop Surg. 2023;18:892.
doi: 10.1186/s13018-023-04338-8
Huo S, Dou D. Circ_0056285 regulates proliferation, apoptosis and Glycolysis of Osteosarcoma cells via miR-1244/TRIM44 Axis. Cancer Manag Res. 2021;13:1257–70.
pubmed: 33603471
pmcid: 7882461
doi: 10.2147/CMAR.S290645
Zhao W, Qin P, Zhang D, Cui X, Gao J, Yu Z, et al. Long non-coding RNA PVT1 encapsulated in bone marrow mesenchymal stem cell-derived exosomes promotes osteosarcoma growth and metastasis by stabilizing ERG and sponging miR-183-5p. Aging. 2019;11:9581–96.
pubmed: 31699956
pmcid: 6874467
doi: 10.18632/aging.102406
Zhu G, Xia Y, Zhao Z, Li A, Li H, Xiao T. LncRNA XIST from the bone marrow mesenchymal stem cell derived exosome promotes osteosarcoma growth and metastasis through miR-655/ACLY signal. Cancer Cell Int. 2022;22:330.
pubmed: 36309693
pmcid: 9617450
doi: 10.1186/s12935-022-02746-0
Zhang H, Wang J, Ren T, Huang Y, Liang X, Yu Y, et al. Bone marrow mesenchymal stem cell-derived exosomal miR-206 inhibits osteosarcoma progression by targeting TRA2B. Cancer Lett. 2020;490:54–65.
pubmed: 32682951
doi: 10.1016/j.canlet.2020.07.008
Qin F, Tang H, Zhang Y, Zhang Z, Huang P, Zhu J. Bone marrow-derived mesenchymal stem cell-derived exosomal microRNA-208a promotes osteosarcoma cell proliferation, migration, and invasion. J Cell Physiol. 2020;235:4734–45.
pubmed: 31637737
doi: 10.1002/jcp.29351
Yang C, Tian Y, Zhao F, Chen Z, Su P, Li Y, et al. Bone microenvironment and Osteosarcoma Metastasis. Int J Mol Sci. 2020;21:6985.
pubmed: 32977425
pmcid: 7582690
doi: 10.3390/ijms21196985
Lagerweij T, Pérez-Lanzón M, Baglio SR. A preclinical mouse model of Osteosarcoma to define the Extracellular vesicle-mediated communication between Tumor and mesenchymal stem cells. J Vis Exp JoVE. 2018;56932.
Zhang L, Cao H, Gu G, Hou D, You Y, Li X, et al. Exosomal MiR-199a-5p inhibits tumorigenesis and angiogenesis by Targeting VEGFA in Osteosarcoma. Front Oncol. 2022;12:884559.
pubmed: 35651811
pmcid: 9148962
doi: 10.3389/fonc.2022.884559
Li Q, Wang X, Jiang N, Xie X, Liu N, Liu J, et al. Exosome-transmitted linc00852 associated with receptor tyrosine kinase AXL dysregulates the proliferation and invasion of osteosarcoma. Cancer Med. 2020;9:6354–66.
pubmed: 32673448
pmcid: 7476833
doi: 10.1002/cam4.3303
Li Y, Lin S, Xie X, Zhu H, Fan T, Wang S. Highly enriched exosomal lncRNA OIP5-AS1 regulates osteosarcoma tumor angiogenesis and autophagy through miR-153 and ATG5. Am J Transl Res. 2021;13:4211–23.
pubmed: 34150009
pmcid: 8205742
Hu X, Wen Y, Tan L-Y, Wang J, Tang F, Wang Y-T, et al. Exosomal Long non-coding RNA ANCR mediates Drug Resistance in Osteosarcoma. Front Oncol. 2021;11:735254.
pubmed: 35096563
doi: 10.3389/fonc.2021.735254
Zhang H, Yu Y, Wang J, Han Y, Ren T, Huang Y, et al. Macrophages-derived exosomal lncRNA LIFR-AS1 promotes osteosarcoma cell progression via miR-29a/NFIA axis. Cancer Cell Int. 2021;21:192.
pubmed: 33794884
pmcid: 8017664
doi: 10.1186/s12935-021-01893-0
Chang X, Tan Q, Xu J, Wu X, Wang Y, Zhang Y, et al. Tumor-derived exosomal linc00881 induces lung fibroblast activation and promotes osteosarcoma lung migration. Cancer Cell Int. 2023;23:287.
pubmed: 37990331
pmcid: 10664679
doi: 10.1186/s12935-023-03121-3
Zhang Y, Chen Y, Chen C, Guo H, Zhou C, Wang H, et al. PITX1 suppresses osteosarcoma metastasis through exosomal LINC00662-mediated M2 macrophage polarization. Clin Exp Metastasis. 2023;40:79–93.
pubmed: 36334221
doi: 10.1007/s10585-022-10192-5
Wang B, Wang X, Li P, Niu X, Liang X, Liu G, et al. Osteosarcoma Cell-Derived Exosomal ELFN1-AS1 mediates macrophage M2 polarization via sponging mir-138-5p and miR-1291 to promote the tumorgenesis of Osteosarcoma. Front Oncol. 2022;12:881022.
pubmed: 35785218
pmcid: 9248260
doi: 10.3389/fonc.2022.881022
Cheng C, Zhang Z, Cheng F, Shao Z. Exosomal lncRNA RAMP2-AS1 derived from Chondrosarcoma Cells promotes Angiogenesis through miR-2355-5p/VEGFR2 Axis. OncoTargets Ther. 2020;13:3291–301.
doi: 10.2147/OTT.S244652
Hou S-M, Lin C-Y, Fong Y-C, Tang C-H. Hypoxia-regulated exosomes mediate M2 macrophage polarization and promote metastasis in chondrosarcoma. Aging. 2023;15:13163–75.
pubmed: 37993261
pmcid: 10713415
doi: 10.18632/aging.205230
Kling MJ, Chaturvedi NK, Kesherwani V, Coulter DW, McGuire TR, Sharp JG, et al. Exosomes secreted under hypoxia enhance stemness in Ewing’s sarcoma through miR-210 delivery. Oncotarget. 2020;11:3633–45.
pubmed: 33088424
pmcid: 7546758
doi: 10.18632/oncotarget.27702
Pachva MC, Lai H, Jia A, Rouleau M, Sorensen PH. Extracellular vesicles in reprogramming of the Ewing Sarcoma Tumor Microenvironment. Front Cell Dev Biol. 2021;9:726205.
pubmed: 34604225
pmcid: 8484747
doi: 10.3389/fcell.2021.726205
Ohno T, Rao VN, Reddy ES. EWS/Fli-1 chimeric protein is a transcriptional activator. Cancer Res. 1993;53:5859–63.
pubmed: 7503813
Huang L, Xiong J, Fu J, Zhou Z, Yu H, Xu J, et al. Bone marrow mesenchymal stem cell-derived exosomal LINC00847 inhibits the proliferation, migration, and invasion of ewing sarcoma. J Clin Transl Res. 2022;8:563–76.
pubmed: 36518202
pmcid: 9741936
Gassmann H, Schneider K, Evdokimova V, Ruzanov P, Schober SJ, Xue B, et al. Ewing Sarcoma-Derived Extracellular vesicles impair dendritic cell maturation and function. Cells. 2021;10:2081.
pubmed: 34440851
pmcid: 8391167
doi: 10.3390/cells10082081
Radu O, Pantanowitz L. Kaposi sarcoma. Arch Pathol Lab Med. 2013;137:289–94.
pubmed: 23368874
doi: 10.5858/arpa.2012-0101-RS
Vangipuram R, Tyring SK. Epidemiology of Kaposi sarcoma: review and description of the nonepidemic variant. Int J Dermatol. 2019;58:538–42.
pubmed: 29888407
doi: 10.1111/ijd.14080
Zheng J, Shi Y, Feng Z, Zheng Y, Li Z, Zhao Y, et al. Oncogenic effects of exosomes in γ-herpesvirus-associated neoplasms. J Cell Physiol. 2019;234:19167–79.
pubmed: 30941765
doi: 10.1002/jcp.28573
Yogev O, Henderson S, Hayes MJ, Marelli SS, Ofir-Birin Y, Regev-Rudzki N, et al. Herpesviruses shape tumour microenvironment through exosomal transfer of viral microRNAs. PLoS Pathog. 2017;13:e1006524.
pubmed: 28837697
pmcid: 5570218
doi: 10.1371/journal.ppat.1006524
Chugh PE, Sin S-H, Ozgur S, Henry DH, Menezes P, Griffith J, et al. Systemically circulating viral and tumor-derived MicroRNAs in KSHV-Associated malignancies. PLoS Pathog. 2013;9:e1003484.
pubmed: 23874201
pmcid: 3715412
doi: 10.1371/journal.ppat.1003484
O’Hara AJ, Chugh P, Wang L, Netto EM, Luz E, Harrington WJ, et al. Pre-micro RNA signatures delineate stages of endothelial cell transformation in Kaposi sarcoma. PLoS Pathog. 2009;5:e1000389.
pubmed: 19381257
pmcid: 2663814
doi: 10.1371/journal.ppat.1000389
Fahs A, Hussein N, Zalzali H, Ramadan F, Ghamloush F, Tamim H, et al. CD147 promotes tumorigenesis via exosome-mediated signaling in Rhabdomyosarcoma. Cells. 2022;11:2267.
pubmed: 35892564
pmcid: 9331498
doi: 10.3390/cells11152267
Sultan I, Qaddoumi I, Yaser S, Rodriguez-Galindo C, Ferrari A. Comparing adult and pediatric rhabdomyosarcoma in the surveillance, epidemiology and end results program, 1973 to 2005: an analysis of 2,600 patients. J Clin Oncol off J Am Soc Clin Oncol. 2009;27:3391–7.
doi: 10.1200/JCO.2008.19.7483
Ramadan F, Saab R, Hussein N, Clézardin P, Cohen PA, Ghayad SE. Non-coding RNA in rhabdomyosarcoma progression and metastasis. Front Oncol. 2022;12:971174.
pubmed: 36033507
pmcid: 9403786
doi: 10.3389/fonc.2022.971174
Parham DM, Barr FG. Classification of rhabdomyosarcoma and its molecular basis. Adv Anat Pathol. 2013;20:387–97.
pubmed: 24113309
pmcid: 6637949
doi: 10.1097/PAP.0b013e3182a92d0d
Rammal G, Fahs A, Kobeissy F, Mechref Y, Zhao J, Zhu R, et al. Proteomic profiling of Rhabdomyosarcoma-Derived exosomes Yield insights into their functional role in Paracrine Signaling. J Proteome Res. 2019;18:3567–79.
pubmed: 31448612
doi: 10.1021/acs.jproteome.9b00157
Paolillo M, Schinelli S. Integrins and exosomes, a dangerous Liaison in Cancer Progression. Cancers. 2017;9:95.
pubmed: 28933725
pmcid: 5575598
doi: 10.3390/cancers9080095
Grass GD, Toole BP. How, with whom and when: an overview of CD147-mediated regulatory networks influencing matrix metalloproteinase activity. Biosci Rep. 2015;36:e00283.
pubmed: 26604323
doi: 10.1042/BSR20150256
Galardi A, Colletti M, Di Paolo V, Vitullo P, Antonetti L, Russo I, et al. Exosomal MiRNAs in Pediatric Cancers. Int J Mol Sci. 2019;20:4600.
pubmed: 31533332
pmcid: 6770697
doi: 10.3390/ijms20184600
Ghayad SE, Rammal G, Ghamloush F, Basma H, Nasr R, Diab-Assaf M, et al. Exosomes derived from embryonal and alveolar rhabdomyosarcoma carry differential miRNA cargo and promote invasion of recipient fibroblasts. Sci Rep. 2016;6:37088.
pubmed: 27853183
pmcid: 5112573
doi: 10.1038/srep37088
Ghamloush F, Ghayad SE, Rammal G, Fahs A, Ayoub AJ, Merabi Z, et al. The PAX3-FOXO1 oncogene alters exosome miRNA content and leads to paracrine effects mediated by exosomal miR-486. Sci Rep. 2019;9:14242.
pubmed: 31578374
pmcid: 6775163
doi: 10.1038/s41598-019-50592-4
Lee ATJ, Thway K, Huang PH, Jones RL. Clinical and molecular spectrum of Liposarcoma. J Clin Oncol off J Am Soc Clin Oncol. 2018;36:151–9.
doi: 10.1200/JCO.2017.74.9598
Sanomachi T, Ishiki H. Classifying and grading liposarcoma by CT. Lancet Oncol. 2024;25:e53.
pubmed: 38301695
doi: 10.1016/S1470-2045(24)00005-6
Tewfik JN, Greene GS. Fluorine-18-deoxyglucose-positron emission tomography imaging with magnetic resonance and computed tomographic correlation in the evaluation of bone and soft-tissue sarcomas: a pictorial essay. Curr Probl Diagn Radiol. 2008;37:178–88.
pubmed: 18502325
doi: 10.1067/j.cpradiol.2007.10.005
Peterson JJ, Kransdorf MJ, Bancroft LW, O’Connor MI. Malignant fatty tumors: classification, clinical course, imaging appearance and treatment. Skeletal Radiol. 2003;32:493–503.
pubmed: 12802520
doi: 10.1007/s00256-003-0647-8
Munk PL, Lee MJ, Janzen DL, Connell DG, Logan PM, Poon PY, et al. Lipoma and Liposarcoma: evaluation using CT and MR imaging. AJR Am J Roentgenol. 1997;169:589–94.
pubmed: 9242783
doi: 10.2214/ajr.169.2.9242783
Sung MS, Kang HS, Suh JS, Lee JH, Park JM, Kim JY, et al. Myxoid liposarcoma: appearance at MR imaging with histologic correlation. Radiogr Rev Publ Radiol Soc N Am Inc. 2000;20:1007–19.
Jelinek JS, Kransdorf MJ, Shmookler BM, Aboulafia AJ, Malawer MM. Liposarcoma of the extremities: MR and CT findings in the histologic subtypes. Radiology. 1993;186:455–9.
pubmed: 8421750
doi: 10.1148/radiology.186.2.8421750
Soulié D, Boyer B, Lescop J, Pujol A, Le Friant G, Cordoliani YS. [Myxoid liposarcoma. MRI imaging]. J Radiol. 1995;76:29–36.
pubmed: 7861366
Murphey MD, Arcara LK, Fanburg-Smith J. From the archives of the AFIP: imaging of musculoskeletal liposarcoma with radiologic-pathologic correlation. Radiogr Rev Publ Radiol Soc N Am Inc. 2005;25:1371–95.
Casadei L, Calore F, Creighton CJ, Guescini M, Batte K, Iwenofu OH, et al. Exosome-derived mir-25-3p and miR-92a-3p stimulate Liposarcoma Progression. Cancer Res. 2017;77:3846–56.
pubmed: 28588009
pmcid: 6033276
doi: 10.1158/0008-5472.CAN-16-2984
Choi JH, Ro JY. The 2020 WHO classification of tumors of soft tissue: selected changes and new entities. Adv Anat Pathol. 2021;28:44–58.
pubmed: 32960834
doi: 10.1097/PAP.0000000000000284
Desai S, Goyal D, Gaitonde A, Osan P, Joshi S. Heavily calcified synovial sarcoma leading to chronic thigh pain and swelling. Skeletal Radiol. 2024;53:821–4.
pubmed: 37819280
doi: 10.1007/s00256-023-04475-5
Sharma J, Deo SVS, Kumar S, Barwad AW, Rastogi S, Sharma DN, et al. Clinicopathological Profile and Survival outcomes in patients with localised extremity synovial sarcomas. Clin Oncol R Coll Radiol G B. 2024;36:e97–104.
doi: 10.1016/j.clon.2024.01.018
Rani H, Rao RV, Badiger S, Holla S. Biphasic synovial sarcoma with epithelial predominance reminiscent of adenocarcinoma: a diagnostic challenge. BMJ Case Rep. 2024;17:e256968.
pubmed: 38242715
doi: 10.1136/bcr-2023-256968
Thway K, Fisher C. Synovial sarcoma: defining features and diagnostic evolution. Ann Diagn Pathol. 2014;18:369–80.
pubmed: 25438927
doi: 10.1016/j.anndiagpath.2014.09.002
Tastsoglou S, Skoufos G, Miliotis M, Karagkouni D, Koutsoukos I, Karavangeli A, et al. DIANA-miRPath v4.0: expanding target-based miRNA functional analysis in cell-type and tissue contexts. Nucleic Acids Res. 2023;51:W154–9.
pubmed: 37260078
pmcid: 10320185
doi: 10.1093/nar/gkad431
R Core Team. R: A language and environment for statistical computing. [Internet]. R Foundation. 2024. https://www.r-project.org/
Samuels M, Jones W, Towler B, Turner C, Robinson S, Giamas G. The role of non-coding RNAs in extracellular vesicles in breast cancer and their diagnostic implications. Oncogene. 2023;42:3017–34.
pubmed: 37670020
pmcid: 10555829
doi: 10.1038/s41388-023-02827-y
Lucas LM, Dwivedi V, Senfeld JI, Cullum RL, Mill CP, Piazza JT et al. The Yin and Yang of ERBB4: Tumor Suppressor and Oncoprotein. Barker E, editor. Pharmacol Rev. 2022;74:18–47.
Ben-Baruch A. Tumor necrosis factor α: taking a Personalized Road in Cancer Therapy. Front Immunol. 2022;13:903679.
pubmed: 35663982
pmcid: 9157545
doi: 10.3389/fimmu.2022.903679
Atay S, Wilkey DW, Milhem M, Merchant M, Godwin AK. Insights into the Proteome of gastrointestinal stromal tumors-derived Exosomes reveals new potential diagnostic biomarkers. Mol Cell Proteom MCP. 2018;17:495–515.
pubmed: 29242380
doi: 10.1074/mcp.RA117.000267
Ye H, Tan L, Tu C, Min L. Exosomes in sarcoma: prospects for clinical applications. Crit Rev Oncol Hematol. 2023;181:103895.
pubmed: 36481305
doi: 10.1016/j.critrevonc.2022.103895
Pérez-Herrero E, Fernández-Medarde A. Advanced targeted therapies in cancer: drug nanocarriers, the future of chemotherapy. Eur J Pharm Biopharm off J Arbeitsgemeinschaft Pharm Verfahrenstechnik EV. 2015;93:52–79.
doi: 10.1016/j.ejpb.2015.03.018
Min L, Shen J, Tu C, Hornicek F, Duan Z. The roles and implications of exosomes in sarcoma. Cancer Metastasis Rev. 2016;35:377–90.
pubmed: 27342745
pmcid: 5037004
doi: 10.1007/s10555-016-9630-4
Elliott RO, He M. Unlocking the power of Exosomes for Crossing Biological barriers in Drug Delivery. Pharmaceutics. 2021;13:122.
pubmed: 33477972
pmcid: 7835896
doi: 10.3390/pharmaceutics13010122
Muskan M, Abeysinghe P, Cecchin R, Branscome H, Morris KV, Kashanchi F. Therapeutic potential of RNA-enriched extracellular vesicles: the next generation in RNA delivery via biogenic nanoparticles. Mol Ther J Am Soc Gene Ther. 2024;S1525-0016(24)00094 – 7.
Shimbo K, Miyaki S, Ishitobi H, Kato Y, Kubo T, Shimose S, et al. Exosome-formed synthetic microRNA-143 is transferred to osteosarcoma cells and inhibits their migration. Biochem Biophys Res Commun. 2014;445:381–7.
pubmed: 24525123
doi: 10.1016/j.bbrc.2014.02.007
Huang X, Wu W, Jing D, Yang L, Guo H, Wang L, et al. Engineered exosome as targeted lncRNA MEG3 delivery vehicles for osteosarcoma therapy. J Control Release off J Control Release Soc. 2022;343:107–17.
doi: 10.1016/j.jconrel.2022.01.026